Regarding the fever marker ... the CEO first brought it up as something they'll look into in ph3. Then, the patients started to notice it. Now, the medical community is picking up on it. I think there is something there.
I agree with your thoughts: either a significant partnership or a buy out. Did you catch that this research was "funded by Eisai, Merck, Genentech, Amgen, BioMimetix Pharmaceutical, Inc., VBL Therapeutics and Agios"?
Some major players funding the research.
News 
Market Data 
Discover 
